Rita Nanda, MD, assistant professor of Medicine, assistant director, Breast Medical Oncology, discusses results from I-SPY 2, which explored pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer.
Dramatic Changes in the RCC Landscape Underscore Importance of Molecular Profiling
June 8th 2023In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Elacestrant Shows Survival Benefit in Certain ER+/HER2- Advanced Breast Cancer
June 4th 2023A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression-free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.
Read More
2 Clarke Drive
Cranbury, NJ 08512